Stage of development
-
PNB-028
PancreatitisInhibition of pancreatic enzymes
- Molecule
- PNB-028
- Indication
- Pancreatitis
- Biological action
- Inhibition of pancreatic enzymes
- Status
- Phase 1 ready
- Information about target and disease
PNB-028 is in clinical testing for Pancreatic Cancer and here the excessive release of amylase and lipase is monitored and antagonized by PNB-028.
Pancreatitis is an unmet medical need and a low hurdle approach through the regulatory approval. Recently Pancreatitis was recognized as emerging disease in India, with rates of incidences of 20 in 100 000 in the general population and significantly higher in Indians in the USA.
- Preclinical studies
PNB-028 was also tested efficient in preclinical models of colon and pancreatic cancers and Pancreatitis.
Cerulein was used in a standard Pancreatitis assay to induce excessive production of pancreatic enzymes leading to Pancreatitis with pain and inflammation. In addition to this standard cerulean assay sincalide, a commercially available cholecystokinin, was used and from 1 mg/kg onwards protection against Acute Pancreatitis was seen. Inflammation and swelling assessed by organ weight was reduced over a dose range dose dependently.
PNB-028 was found highly efficient in vitro and in vivo in mice in the treatment of experimentally induced Pancreatitis by oral administration. Cholecystokinin is physiologically leading to the release of pancreatic enzymes in the target organ - the pancreas and the CCK antagonist PNB-028 offers the first targeted efficient treatment for Acute Pancreatitis.
- Preclinical development studies
PNB-028 is in terms of binding profile equivalent to devazepide, but has an excellent pharmacokinetics with high oral bioavailability, as well as very high membrane penetration.
DMPK studies with PNB-081 indicated, that similar to PNB-028, was highly stable in rat, dog, and human liver microsomes. PNB-028 was also highly available in rats with >80% bioavailability. Other studies, including CaCo2 permeability and plasma protein binding demonstrated favorable druggable properties of PNB-028.
- Intellectual property
Since PNB-081 belongs to the same class as PNB-028 or PNB-001, its chemical structure is also well protected until 2037 (including 5 years of extension) in most of the countries around the World.
About PNB-028
Clinical · Phase 1/2a ongoing
A targeted oncology molecule in a DCGI-approved combined Phase 1/2 trial for pancreatic and Colorectal Cancer, with Acute Pancreatitis as a further target-based indication.
PNB-028 full profileOther indications of PNB-028
All moleculesInterested in a programme?
PNB Vesper welcomes discussions on clinical development, licensing, co-development and investment for any molecule in the pipeline.
